Abstract Submission is Open
Abstract Submission Deadlines
All abstract submissions for an ESMO Virtual Plenary must be completed by 12:00hrs CET on the dates listed below:
Abstract submission deadline |
For ESMO Virtual Plenary presentation |
|---|---|
Friday, 12 November 2021 |
Thursday, 16 December 2021 |
Friday, 10 December 2021 |
Thursday, 20 January 2022 |
Monday, 10 January 2022 |
Thursday, 10 February 2022 |
Friday, 11 February 2022 |
Thursday, 17 March 2022 |
Friday, 11 March 2022 |
Thursday, 21 April 2022 |
Friday, 8 April 2022 |
Thursday, 12 May 2022 |
Tuesday, 10 May 2022 |
Tuesday, 14 June 2022 |
Friday, 10 June 2022 |
Thursday, 14 July 2022 |
Friday, 16 September 2022 |
Thursday, 20 October 2022 |
Friday, 14 October 2022 |
Thursday, 17 November 2022 |
Friday, 11 November 2022 |
Wednesday, 14 December 2022 |
Eligibility for Submission
Abstracts containing original scientific data from randomized phase III trials in oncology, or from phase II trials which demonstrate remarkable therapeutic benefit, scientific insight or progress in an area of unmet need.
Real world data studies will be considered for eligibility based on scientific interest.
Submission Categories
- Basic science
- Biliary tract cancer, incl. cholangiocarcinoma
- Biomarkers (agnostic)
- Breast cancer, early stage
- Breast cancer, locally advanced
- Breast cancer, metastatic
- CNS tumours
- Colorectal cancer
- Developmental therapeutics
- Endocrine tumours
- Genitourinary tumours, prostate
- Genitourinary tumours, non-prostate
- Gynaecological cancers
- Haematological malignancies
- Head and neck cancer, excluding thyroid
- Hepatocellular carcinoma (HCC)
- Investigational immunotherapy
- Melanoma and other skin tumours
- Miscellaneous
- Neuroendocrine tumours
- New diagnostic tools
- NSCLC, early stage
- NSCLC, locally advanced
- NSCLC, metastatic
- Oesophagogastric cancer
- Palliative care
- Pancreatic cancer
- Psycho-oncology
- Public policy
- Sarcoma
- SARS-CoV-2 and cancer
- SCLC
- Supportive care
- Thoracic malignancies, other
- Thyroid cancer
- Translational research (agnostic)
- Tumour biology and pathology
Review and Publication of Accepted Abstracts
Submitted abstracts will be reviewed by the the ESMO Virtual Plenary Review Panel comprising the ESMO President, ESMO President-elect, ESMO Chief Medical Officer, ESMO Congress Scientific Chairs and the appropriate Scientific Track Chairs.
Accepted abstracts will be granted an oral presentation by the first author, followed by expert perspectives and an interactive panel and audience discussion / Q&A session.
Presented abstracts will be published in Annals of Oncology as well as on the Annals of Oncology and ESMO websites.